The hottest interpretation of the domestic pharmac

  • Detail

Interpretation of the domestic pharmaceutical packaging market (Part 2)

inventory of pharmaceutical packaging laws and regulations with the sustained and healthy economic development, China has become one of the world's top ten pharmaceutical producers and raw material exporters. However, at present, the overall level of pharmaceutical packaging in China still lags behind developed countries. In addition to technical and management reasons, a very important point also lies in the legal environment, including legislation, justice, legal awareness and many other aspects, The legal issues involved in pharmaceutical packaging are quite extensive, involving not only domestic laws, but also foreign laws and international standards. Among them, trademark, patent, copyright, anti unfair competition, consumer protection, environmental protection, product quality standards and other legal issues are closely related to pharmaceutical packaging. It is understood that in China's trademark registration system, the use and parameters of voluntary registration are the main ones, but the compulsory registration of human drugs and tobacco products is given, because human drugs are related to the life, health and safety of ordinary people. In other words, drugs with unregistered trademarks will be regarded as fake drugs when they enter the market. In China's patent law, the edible commodities that apply for design protection mainly include food and alcohol products, while the pharmaceutical packaging applies for conceptual design protection less, but the pharmaceutical packaging of specialty drugs, high-grade drugs and drugs that can be given as gifts must pay attention to design patents. At the same time, China's "Anti Unfair Competition Law" stipulates that the unauthorized use of the unique name, packaging and decoration of well-known goods, the forgery or fraudulent use of certification marks, famous and high-quality marks, the use of false text descriptions, and the defamation of the goodwill of competitors will constitute unfair competition and must bear the corresponding laws. It can be predicted that the market economy is a legal economy. While carrying out the technical design of China's pharmaceutical packaging, we should also pay attention to the unavoidable legal issues, which will play a positive role in promoting the healthy development of China's pharmaceutical packaging industry and even the pharmaceutical industry, enhancing international competitiveness and the ability to resist risks. Looking at foreign pharmaceutical packaging, the laws and regulations related to packaging have relatively strict provisions. The Ministry of health of Canada has formulated a series of regulations on strengthening the management of Chinese herbal medicine and its products, such as the food and drug safety management act and the drug identification number management act. It is stipulated that any product with therapeutic effect should be treated as a drug, and products that do not meet the health standards are not allowed to be listed. All Chinese herbal medicine products must apply for a drug license from Health Canada, that is, a drug identification number management license. In addition, the United States Department of agriculture has also made new regulations on the packaging of all imported products, including Chinese herbal medicine. All pure wood packaging materials must be treated with high-temperature fumigation material properties or protective agents, otherwise all transported goods will be refused entry. France has stricter regulations on wood packaging, stipulating that all imported products are not allowed to use wood packaging. The U.S. Food and drug administration has formulated corresponding regulations for all links of drug sales, and stipulated that all drug-related materials should be subject to clinical scientific testing. The content of drug labels must not only include the use of drugs, precautions for use by special groups (such as children, pregnant women, etc.), dosage instructions, use methods and time, but also indicate the side effects, contraindications and efficacy of drugs. Any label that does not meet the requirements of the regulations is recognized as a "false label", which is a serious violation of federal law. In order to advertise drugs or provide relevant promotional materials, the content must be exactly the same as that of the label, and there must be no other materials without approval or beyond the scope of the label. With the reform of China's medical system, the disorder and backwardness of pharmaceutical packaging will fundamentally change. At present, China is constantly introducing and updating pharmaceutical packaging machinery and materials, and the pharmaceutical packaging industry will present a new situation. The diversification of drug types also brings diversification to the forms of pharmaceutical packaging. In recent years, the packaging of solid drugs in China, such as plain tablets, capsules, injections and externally applied drugs, has been updated rapidly. At the same time, the use of disposable plastic syringes has brought a major change to the packaging and application of injections in China. The improvement of large infusion packaging is also moving towards the direction of composite flexible packaging bags and plastic bottle packaging. The "analysis report on the prosperity of China's pharmaceutical industry in the second quarter of 2003", jointly launched by the Economic Research Institute of the national development and Reform Commission and Beijing Xinhua Information Technology Co., Ltd., shows that affected by SARS, medicine became the first in the production growth of all industries in the second quarter of this year. In January this year, the pharmaceutical industry achieved a total industrial output value of 143.362 billion yuan (at current prices), an increase of 21.55% over the same period last year; According to the statistics of constant prices, the total output value of the pharmaceutical industry was 183.09 billion yuan, an increase of 24.82%. In a word, looking at the prospects of China's pharmaceutical development in the next few years, we can predict the rapid development of China's pharmaceutical packaging in the future. According to the report of the American flexible packaging Association, by 2003, the demand for basic packaging of pharmaceutical products in the world will increase by 4.2%, and the total output value will reach US $11.2 billion. In the next five years, the pharmaceutical packaging industry will become the second largest economic growth point of the flexible packaging industry. To seize this opportunity, experts believe that China's pharmaceutical packaging should do the following: first, accelerate the promotion and application of plastic containers for pharmaceutical oral liquids; Second, to speed up the development of plastic hollow container packaging of traditional Chinese medicine, we should use more plastic hollow containers made of HDPE, PP, pet, pen and other materials and using injection blow molding and other molding processes. The mouth of the hollow container is sealed with aluminum foil electromagnetic induction gasket to enhance the safety protection of drugs, and speed up the promotion and application of plastic composite membrane bag packaging of traditional Chinese medicine. It should be said that pharmaceutical packaging will develop rapidly in the next few years, with good prospects and large space. In the future, there will be more and more single dose packaging of drugs, and foreign pharmaceutical enterprises also began to pour into the Chinese market. How to seize this opportunity is worth thinking about for Chinese pharmaceutical packaging enterprises. Director Ji believes that first of all, we should strengthen the R & D capacity of enterprises and improve the grade of packaging materials. In the future, the trend of oligopoly of pharmaceutical real-time display water volume curve enterprises will become more and more obvious, and their procurement will be collectivized, which is a severe challenge for packaging materials enterprises, which requires pharmaceutical packaging enterprises to have a long-term vision and implement the development strategy of going out and standing; We should constantly innovate in new materials and products, have our own R & D team, have packaging products with independent property rights, and take the road of high-quality packaging and green packaging. Secretary General Chen believes that although traditional Chinese medicine has a history of thousands of years, it has failed to enter the European and American markets on a large scale. In addition to the outdated production technology and some prejudice of European and American countries against traditional Chinese medicine, the failure of pharmaceutical packaging to implement national standards is also an important reason. The standard of traditional Chinese medicine (TCM) has been a barrier for TCM manufacturers to expand to overseas markets. From the perspective of the market, the culprit of the difficulty in exporting Chinese patent medicine is actually the problem of material selection rather than the packaging material itself. In this regard, director Ji believes that it is wise to choose appropriate packaging materials according to the characteristics of drugs. At the same time, we should develop green packaging, protect the environment and promote the sustainable development of society. After China's accession to the WTO, tariff barriers have been gradually eliminated, but technical barriers and environmental barriers are gradually forming. How to grasp the future development trend is worthy of enterprises' attention. After China's entry into WTO, domestic pharmaceutical enterprises will actively participate in the competition in the international market. Secretary General Chen said that in order to eliminate the technical barriers caused by medical packaging and other reasons for the fact that each scale of Rockwell hardness has 1 scope of application, advanced packaging equipment and materials meeting international standards will be required to cooperate with its development, which also puts forward higher requirements and broader market space for domestic pharmaceutical packaging enterprises. From the perspective of the enterprise itself, the packaging of drugs should be more concise, clear and beautiful. On the premise of ensuring that it is not easy to be damaged during transportation, materials should be saved as much as possible, and excessive packaging should not be allowed. The market competitiveness of the enterprise should be improved by continuously improving the quality of its employees. The national macro-control department should also speed up the legislative work of packaging, raise the technical threshold, and constantly guide the benign development of enterprises through macro-control

Copyright © 2011 JIN SHI